Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Key highlights for the quarter include:
- Record revenue for the quarter of $3.0 million driven primarily by Remplir’s growing market penetration in Australia and Singapore
- Orthocell maintains robust cash reserves of $27 million in cash as at 30 September 2025 and is well-positioned for continued commercial expansion
- Remplir rollout in the US$1.6 Billion US market ahead of schedule, with Distribution networks now spanning 25 states and reaching 40% of the US population, and first surgeries complete
- First distributor appointed for Remplir in US$75 million Canadian market, with first sales targeted for December 2025 Quarter
- Remplir used in nerve-sparing prostate cancer surgery
- Remplir study results deliver compelling 81% success rate
- Strengthened leadership with Executive and Board appointments
Orthocell CEO and MD, Paul Anderson, said:
“We have continued to build strong commercial momentum in the September quarter with another record quarter of sales revenue delivered primarily from Remplir sales in our existing markets in Australia and Singapore.”